Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fragment-based discovery of pyrazole-5-carboxamide derivatives as ALK inhibitors against non-small cell lung cancer.

Bioorganic chemistryĀ·2026
Same author

Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.

Bioorganic & medicinal chemistryĀ·2026
Same author

Proline, a privileged fragment in drug design: advances and future perspectives.

European journal of medicinal chemistryĀ·2026
Same author

Koumine from Gelsemium elegans Benth suppresses colorectal cancer metastasis by inhibiting vasculogenic mimicry formation through epithelial-mesenchymal transition and cytoskeleton remodeling.

European journal of pharmacologyĀ·2026
Same author

TRK inhibitors in cancer therapeutics: Recent advances and future perspectives.

Bioorganic chemistryĀ·2026
Same author

Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification.

Bioorganic chemistryĀ·2025

Related Experiment Video

Updated: Jul 8, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

328

Small molecular CD73 inhibitors: Recent progress and future perspectives.

Gong-Hui Ge1, Qiu-Yin Wang1, Zhen-Hao Zhang1

  • 1School of Pharmacy / Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China.

European Journal of Medicinal Chemistry
|December 12, 2023
PubMed
Summary

Inhibiting CD73, an enzyme crucial for tumor growth and metastasis, can reduce adenosine-mediated immunosuppression. This approach offers a promising strategy for developing novel small-molecule antitumor drugs against solid tumors.

Keywords:
AdenosineCD73Structure-activity relationship

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K

Related Experiment Videos

Last Updated: Jul 8, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

328
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Tumor occurrence and development are complex biological processes.
  • CD73 is increasingly recognized for its role in tumor growth and metastasis.
  • Extracellular ATP hydrolysis to adenosine is a key immunosuppressive pathway in the tumor microenvironment.

Purpose of the Study:

  • To review the research progress on the CD73 enzyme.
  • To discuss the development of CD73 small molecule inhibitors.
  • To provide insights for developing CD73-targeting antitumor drugs.

Main Methods:

  • Literature review of CD73 enzyme research.
  • Analysis of studies on CD73 small molecule inhibitors.
  • Synthesis of current understanding of adenosine-mediated immunosuppression in tumors.

Main Results:

  • CD73 plays a significant role in tumor progression and immune evasion.
  • Adenosine, produced by CD73, suppresses immune cells via receptors like A2A.
  • Inhibiting CD73 can potentially reverse tumor-induced immunosuppression.

Conclusions:

  • Targeting CD73 is a promising strategy for solid tumor treatment.
  • CD73 small molecule inhibitors represent a potential therapeutic avenue.
  • Further research into CD73 inhibitors could lead to novel antitumor drugs.